

WORLDWIDE
CLINICAL TRIALS

DEDICATED TO PROVIDING UNCOMMON EXPERTISE FOR YOUR ONCOLOGY PROGRAM

Last Update: 13112020

DEDICATED ONCOLOGY OPERATIONAL AND SCIENTIFIC TEAMS

GLOBAL REACH FOR FASTER RECRUITMENT AND START-UP

Cancer spans the globe. Frequently, cancer therapies are targeting small subsets of patients with rare mutations or patients that have been treated with a very specific therapeutic regimen. Our long-term relationships with successful, experienced sites and oncology centers worldwide help us recruit patients faster than ever before, accelerate study start-up, and navigate the global regulatory landscape to expedite approvals.

> *"Worldwide Clinical Trials opened a site in Germany in record time – fewer than 3 months from the first contract day to the initiation visit. I am very pleased with the expedited work done by Worldwide. Job well done!"*
>
> *– Worldwide Customer (Global Project Management)*

1,900+ Professionals

Real Offices in Emerging Markets for Access to Hard-to-Find Oncology Patients Across

60+ Countries

300+ clinical staff with 2+ years' experience in hematology/ oncology trials

Our award-winning, specialized early phase oncology team helps emerging and established biopharma, biotech, and pharmaceutical companies accelerate the advancement of early phase compounds through clinical testing.

YOUR CANCER THERAPY SHOWS PROMISE. GET ON YOUR WAY TO FDA APPROVAL FASTER AND EASIER WITH WORLDWIDE.

The competitive landscape for oncology research is at an all-time high, and trial designs are increasing in complexity. Recent reports indicate that the success rate of investigational compounds approved for clinical use in cancer is the lowest among all diseases, and the likelihood of approval for investigational oncology drugs tested in Phase I trials is only 6.7 percent.[1] Who you select as your CRO partner can have a significant impact on the success and/or failure of your clinical study and program. Who can you trust to help you with your development journey?

> ***"From the moment of involvement in the study, we felt Worldwide's support, experience, knowledge, and ability to help in difficult situations. All the materials, trainings, meetings organized by Worldwide personnel within the study were very helpful and informative."***
>
> *- Investigator, Cancer Center*

OF OUR CURRENT ONCOLOGY PORTFOLIO...

44%

Is focused on immuno-oncology, including but not limited to checkpoint inhibitors, oncolytic virus, T-cell engagers, vaccines, among other trial molecules as single or combined agents.

67%

Are early phase trials from first-in-human to proof-of-concept and Phase I/II dose finding studies.

100%

Of our project management team has immuno-oncology experience across a variety of products, including CAR-Ts, gene therapies, checkpoint inhibitors, immuno-modulators, and cancer vaccines.

[1] *Pharmaceutical Research and Manufacturers of America. Medicines in development: Cancer [online], 2014. Available at http://www.phrma.org/sites/default/files/pdf/2014-cancer-report.pdf.*

Last Update: 13112020

WORLDWIDE CLINICAL TRIALS

HEMATOLOGY/ONCOLOGY/ SUPPORTIVE CARE PORTFOLIO

- Advanced Solid Tumors
- Breast Cancer
- Cervical Cancer
- Chemo-induced Anorexia or Cachexia
- Colorectal Cancer
- Endometrial Cancer
- Glioblastoma (GBM)
- Hepatocellular Carcinoma
- Idiopathic Thrombocytopenia Purpura
- Leukemia, Acute Myeloid
- Lung Cancer, Non-Small Cell
- Melanoma
- Myelodysplastic Syndrome
- Non-Hodgkin's Lymphoma
- Ovarian Cancer
- Pancreatic Cancer
- Prostate Cancer
- Renal Cell Carcinoma
- Sickle Cell Disease
- Stomach Cancer

CRO LEADERSHIP AWARDS 2020
Capabilities, Compatibility, Expertise, Quality, and Reliability

ISR reports

RATED OVERALL TOP PERFORMER FOR:

- Budget Factors
- Delivery Factors
- Staff Characteristics
- Accessibility
- Services
- Customer Loyalty

+1 610 964 2000 | WORLDWIDE.COM

A SPECIALIZATION IN EARLY PHASE ONCOLOGY PROGRAMS FOR ACCELERATED TRIALS

Whether your study is a small, focused single-region trial or a study that requires global reach, we designed our specialty oncology team – oncologists; experienced clinical monitors and project managers; regulatory, data management, statistical, scientific, and medical experts – to work collaboratively with you to help you overcome the high-risk, high-cost, time-intensive challenges of early phase oncology drug development.

- We've conducted research in a full range of solid tumor and hematologic indications and therapies – **from traditional cytotoxic agents to cutting-edge cellular and immuno-oncology targeted therapies**.
- We work with you to customize your protocol and study design for an optimal outcome. With Worldwide, every study is appointed a dedicated team of in-house Scientific Solutions and Operational advisors, who are committed to ensuring you get through the critical early stage of testing and on your way to FDA approval.
- With Worldwide, you get a **committed executive management team**, engaged at all times throughout the course of your program to help ensure the successful execution and delivery of your trial.
- Our relationships with key oncology opinion leaders provide you access to vital counsel – critical to understanding your product's life cycle as well as what is required to accelerate your treatment to market.

Rated Top Performer Service Providers Performance and Loyalty for "Budget Factors" – attributes include Low Cost and Minimizing Change Orders.

Source: ISR Reports CRO QUALITY BENCHMARKING – PHASE I SERVICE PROVIDERS (8TH EDITION)

WORLDWIDE HAS A STRONG COMMITMENT TO DATA INTEGRITY AND RISK MANAGEMENT, IN ALIGNMENT WITH THE REQUIREMENTS OF ICH GCP E6.

We leverage the Comprehend clinical trial software platform to provide a robust solution of oversight and central monitoring. Comprehend, along with EDC-specific targeted SDV tools, can provide the flexibility to execute most risk-based monitoring (RBM) strategies.



RISK MANAGEMENT PLAN

Last Update: 13112020



WORLDWIDE HEMATOLOGY/ONCOLOGY/ SUPPORTIVE CARE EXPERIENCE

EXPERIENCE MATTERS. WORK WITH A PROFICIENT, TRUSTWORTHY PARTNER.

Does your CRO partner have the experience to back up its claims? With an early phase focus for over 20 years, we currently conduct approximately 100 clinical trials annually.

12,500+

Patients treated in hematology/ oncology trials

STUDIES BY PHASE

Full-service* hematology/oncology/ supportive care trials conducted

25% **PHASE I STUDIES**
excluding healthy humans studies

32% **PHASE II STUDIES**

25% **PHASE III STUDIES**

8% **PHASE IV STUDIES**
Non-Interventional studies

8% **PHASE IV STUDIES**
Interventional and IV Non-Interventional studies

**Full-service studies defined as Phase I (excluding healthy humans), Phase II, III, IV-Interventional and IV Non-Interventional that included Project Management, Clinical Monitoring and Study Start-up Services since 1992.*



Indication	Patients
Acute Myelocytic Leukemia (AML)	172
Advanced Solid Tumors	314
Breast Cancer	696
Cancer (Other)	216
Cervical Cancer	1,183
Chemo induced anorexia or cachexia	252
Colorectal Cancer	1,564
Endometrial Cancer	10
Gastrointestinal Stromal Tumor (GIST)	60
Glioblastoma Multiforme (GBM)	185
Hepatocellular Carcinoma	212
Idiopathic Thrombocytopenia Purpura	60
Melanoma	354
Myelodysplastic Syndrome	60
Non-Hodgkins Lymphoma	144
Non-Small Cell Lung Cancer	5,351
Ovarian Cancer	15
Pancreatic Cancer	30
Post-Essential Thrombocythemia Myelofibrosis (Post-ET MF)	46
Prostate Cancer	585
Proteus Syndrome	15
Renal Cell Carcinoma	37
Sickle Cell Disease	277
Solid Tumor	500
Stomach Cancer	120
Tenosynovial Giant Cell Tumor	120
Total	12,578

Last Update: 13112020